The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells

Cancer Chemother Pharmacol. 1992;31(1):23-31. doi: 10.1007/BF00695990.

Abstract

A mitomycin C (MMC)- and porfiromycin (PFM)-resistant subline of the HCT 116 human colon-cancer cell line was isolated after repeated exposure of HCT 116 cells to increasing concentrations of MMC under aerobic conditions. The MMC-resistant subline (designated HCT 116-R30A) was 5 times more resistant than the parent cells to MMC and PFM under aerobic conditions. Both the MMC-resistant cells and the parent HCT 116 cells accumulated similar amounts of PFM by passive diffusion, but levels of macromolecule-bound PFM were about 50% lower in the resistant cell line, implying a decrease in PFM reductive activation in the resistant cells. The finding that microsomes from either sensitive or resistant cells showed an equal ability to reduce MMC and PFM indicated that the activity of NADPH cytochrome P-450 reductase (EC 1.6.2.4) was not changed in the resistant subline. Soluble extracts of HCT 116 cells reduced MMC and PFM more effectively at pH 6.1, and NADH and NADPH were utilized equally well as electron donors under both aerobic and anaerobic conditions. These data suggest that quinone reductase (EC 1.6.99.2; DT-diaphorase) in soluble extracts is responsible for the reduction of MMC. Quinone reductase activities in soluble extracts of HCT 116-R30A cells for the reduction of dichlorophenol indophenol (DCPIP) and menadione-cytochrome c at optimal pHs were decreased by 95% as compared with those obtained in parent cells. However, the MMC-reducing activity of HCT 116-R30A soluble extracts was only 50% lower than that of the parent cell extracts. The kinetic constants (Km, Vmax) found for quinone reductase in the two cell lines with respect to the substrates DCPIP and menadione differed. Two species of mRNA for quinone reductase (2.7 and 1.2 kb) were detected in both cell lines, and there was no detectable difference between parent and resistant cells in the steady-state level of either of these mRNA species. Furthermore, incubation with the quinone reductase inhibitor dicoumarol rendered HCT 116 cells more resistant to MMC. Alteration of the quinone reductase activity in HCT 116-R30A cells appears to be the mechanism responsible for their resistance to MMC and PFM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2,6-Dichloroindophenol / metabolism
  • Carbon Radioisotopes
  • Cell Extracts
  • Cell Size / physiology
  • Cell Survival / drug effects
  • Cell Survival / physiology
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / enzymology*
  • Colonic Neoplasms / genetics
  • Drug Resistance
  • Drug Screening Assays, Antitumor
  • Humans
  • Intracellular Fluid / metabolism
  • Microsomes / metabolism
  • Mitomycin / metabolism
  • Mitomycin / pharmacology*
  • NAD(P)H Dehydrogenase (Quinone) / genetics
  • NAD(P)H Dehydrogenase (Quinone) / physiology*
  • Oxidation-Reduction
  • Porfiromycin / pharmacokinetics
  • Porfiromycin / pharmacology*
  • RNA, Messenger / genetics
  • Tissue Distribution
  • Transcription, Genetic / genetics
  • Tumor Cells, Cultured / drug effects
  • Vitamin K / metabolism

Substances

  • Carbon Radioisotopes
  • Cell Extracts
  • RNA, Messenger
  • Vitamin K
  • Mitomycin
  • 2,6-Dichloroindophenol
  • NAD(P)H Dehydrogenase (Quinone)
  • Porfiromycin